Who are NICARDIPINE HYDROCHLORIDE's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Vitamin D and calcium supplementation, Vitamin D and Calcium, Cleviprex, Sular, Norvasc, Plendil.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nicardipine-hydrochloride.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

NICARDIPINE HYDROCHLORIDE — Competitive Intelligence Brief

NICARDIPINE HYDROCHLORIDE (NICARDIPINE HYDROCHLORIDE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium channel blocker. Area: Cardiovascular.

marketed Calcium channel blocker Calcium ion channels Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

NICARDIPINE HYDROCHLORIDE (NICARDIPINE HYDROCHLORIDE). Nicardipine blocks calcium ion influx into vascular smooth muscle, causing relaxation with minimal effect on cardiac muscle.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
NICARDIPINE HYDROCHLORIDE TARGET	NICARDIPINE HYDROCHLORIDE		marketed	Calcium channel blocker	Calcium ion channels	1988-01-01
Vitamin D and calcium supplementation	Vitamin D and calcium supplementation	Hoffmann-La Roche	marketed	Nutritional supplement / mineral and vitamin combination	Vitamin D receptor (VDR); calcium ion channels and transporters
Vitamin D and Calcium	Vitamin D and Calcium	Lady Hardinge Medical College	marketed	Nutritional supplement / Mineral and vitamin combination	Vitamin D receptor (VDR); calcium ion channels and binding proteins
Cleviprex	CLEVIDIPINE	Chiesi	marketed	Dihydropyridine Calcium Channel Blocker [EPC]	Voltage-dependent L-type calcium channel subunit alpha-1C	2008-01-01
Sular	NISOLDIPINE	Azurity	marketed	Dihydropyridine Calcium Channel Blocker [EPC]	Voltage-dependent L-type calcium channel subunit alpha-1C	1995-01-01
Norvasc	amlodipine	Pfizer Inc.	marketed	Calcium channel blocker (dihydropyridine)	Aldehyde oxidase, Voltage-dependent calcium channel gamma-1 subunit, 5-hydroxytryptamine receptor 6	1992-07-31
Plendil	FELODIPINE	AstraZeneca	marketed	Dihydropyridine Calcium Channel Blocker [EPC]	Voltage-dependent T-type calcium channel subunit alpha-1H	1991-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-04-18 — NICARDIPINE HYDROCHLORIDE · 8455524 · Method of Use · US
2027-04-18 — NICARDIPINE HYDROCHLORIDE · 7659291 · Method of Use · US
2027-04-18 — NICARDIPINE HYDROCHLORIDE · 11547758 · Method of Use · US
2027-04-18 — NICARDIPINE HYDROCHLORIDE · 10758616 · Formulation · US
2027-12-26 — NICARDIPINE HYDROCHLORIDE · 9364564 · Formulation · US
2027-12-26 — NICARDIPINE HYDROCHLORIDE · 7612102 · Formulation · US

Sponsor landscape (Calcium channel blocker class)

Shenzhen Ausa Pharmed Co.,Ltd · 2 drugs in this class
Boryung Pharmaceutical Co., Ltd · 2 drugs in this class
Ain Shams University · 1 drug in this class
Bioprojet · 1 drug in this class
Bristol-Myers Squibb · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Handok Inc. · 1 drug in this class
Hasten Biopharmaceutical Co., Ltd. · 1 drug in this class
Hospital de Clinicas de Porto Alegre · 1 drug in this class
Laboratorios Richmond S.A.C.I.F. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NICARDIPINE HYDROCHLORIDE — Competitive Intelligence Brief. https://druglandscape.com/ci/nicardipine-hydrochloride. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab